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Polycystic ovary syndrome (PCOS) is a complex hormonal disorder
characterized by reproductive, endocrine, and metabolic abnor-
malities. As the origins of PCOS remain unknown, mechanism-
based treatments are not feasible and current management relies
on treatment of symptoms. Hyperandrogenism is the most consistent
PCOS characteristic; however, it is unclear whether androgen excess,
which is treatable, is a cause or a consequence of PCOS. As androgens
mediate their actions via the androgen receptor (AR), we combined
a mouse model of dihydrotestosterone (DHT)-induced PCOS with
global and cell-specific AR-resistant (ARKO) mice to investigate the
locus of androgen actions that mediate the development of the
PCOS phenotype. Global loss of the AR reveals that AR signaling is
required for all DHT-induced features of PCOS. Neuron-specific AR
signalingwas required for the development of dysfunctional ovulation,
classic polycystic ovaries, reduced large antral follicle health, and
several metabolic traits including obesity and dyslipidemia. In addition,
ovariectomized ARKO hosts withwild-type ovary transplants displayed
normal estrous cycles and corpora lutea, despite DHT treatment,
implying extraovarian and not intraovarian AR actions are key loci of
androgen action in generating the PCOS phenotype. These findings
provide strong evidence that neuroendocrine genomic AR signaling is
an important extraovarianmediator in the development of PCOS traits.
Thus, targeting AR-drivenmechanisms that initiate PCOS is a promising
strategy for the development of novel treatments for PCOS.
PCOS | androgen | animal model | neuroendocrine
Polycystic ovary syndrome (PCOS) is the most frequent en-docrine disorder of young women, with a prevalence of 6 to
15% (1), and accounts for more than 75% of anovulatory in-
fertility (2). It is characterized by reproductive hormone dysre-
gulation involving luteinizing hormone (LH) hypersecretion and
hyperandrogenism (3), the consequences of which can be acne and
hirsutism, as well as reduced fertility, due to aberrant follicular mat-
uration, ovulatory disturbance, and miscarriage (3). Associated non-
reproductive abnormalities, such as obesity, metabolic syndrome,
hyperinsulinemia, insulin resistance, hepatic steatosis, and dyslipidemia
predispose affected women to heightened risk of cardiovascular dis-
ease and type 2 diabetes (3, 4). However, despite the high prevalence
and significant health impact, the pathogenesis of PCOS remains
unclear so that mechanism-based treatments remain unattainable.
Hyperandrogenism, the most consistent feature of PCOS (5), is
implicated as a key mediator in the pathogenesis of PCOS. Sup-
portive evidence includes that androgen excess from endogenous
[congenital adrenal hyperplasia (6)] or exogenous [female-to-male
transsexuals (7)] sources can produce polycystic ovaries. Further-
more, androgens induce reproductive, metabolic, and endocrine
features of PCOS in rodent, sheep, and primate animal models of
PCOS (8–10). As all androgen action is mediated via the androgen
receptor (AR), AR-mediated actions are thereby strongly impli-
cated in the development of PCOS. Support for AR-mediated an-
drogen actions influencing the progression of PCOS includes that
variation in androgen sensitivity via the CAG triplet repeat length
polymorphism of the AR (11) is associated with PCOS prevalence
(12), and alternative splicing of the AR in granulosa cells is associ-
ated with aberrant follicle development (13, 14). Treatment with the
AR antagonist flutamide is reported to restore ovulation in some
women with PCOS (15) and rescue acyclicity (16) and anxiety-like
behavior (17) in PCOS mouse models. Moreover, we recently
identified that loss of AR signaling protects female mice from in-
duction of PCOS features by prenatal hyperandrogenism (18).
Animal models have shown that systemic treatment with andro-
gens induces PCOS-like clinical features (19); however, systemic
treatments cannot elucidate the target tissue(s) of androgenic actions.
Although the naming of PCOS implies a primarily ovarian condition,
it has yet to be established whether the disorder originates in the
ovary or elsewhere, with ovarian manifestations as downstream ram-
ifications.We hypothesize that androgens are central in the etiology of
PCOS, so in the current study we combined an optimized PCOS
mouse model (20, 21) with global and neuron- and granulosa cell-
specific androgen receptor knockout (ARKO) mouse lines (22, 23) to
identify the sites of androgen action (Fig. 1). Our findings highlight
the importance of extraovarian AR-mediated androgen actions in the
origins of PCOS features, which is strongly supported by findings from
recent genome-wide association studies (GWAS) of PCOS high-
lighting the importance of gonadotropins in PCOS (24–26).
Results
Neuron but Not Granulosa Cell AR Signaling Is Required for the
Development of Anovulation in the PCOS Mouse Model. Irregular
menstruation is a key diagnostic criterion for PCOS. The development
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of PCOS-like features in our mice was confirmed by the detection of
acyclicity in 100% of WT females treated with dihydrotestosterone
(DHT) (P < 0.01; Fig. 2A and Fig. S1), as well as in neuron-specific
wild-type (NeurWT) (100% acyclic; P < 0.01) and granulosa cell-
specific wild-type (GCWT) (75% acyclic; P < 0.01; two of the eight
mice exhibiting only one long irregular cycle) females, relative to non-
DHT–treated controls. In contrast, ARKO, but not NeurARKO or
GCARKO (granulosa cell-specific androgen receptor knockout female
mice), females maintained normal estrous-cycle patterns after DHT
treatment, hence global AR inactivation protected against the devel-
opment of the PCOS trait of aberrant cycles (Fig. 2A and Fig. S1).
Similarly, oligo/anovulation is a key reproductive characteristic of
PCOS. Histologically, the number of corpora lutea (CL) present was
notably diminished in DHT-treated WT, NeurWT, GCWT, and
GCARKO groups, demonstrating oligo/anovulation (P < 0.01; Fig. 2
B and C). Conversely, global loss of AR signaling protected against
the induction of ovulatory dysfunction (Fig. 2 B and C). Loss of AR
signaling in granulosa cells allowed the development of DHT-induced
irregular estrous cycles and ovulatory dysfunction, with GCARKO
females exhibiting a significant reduction in completed estrous cycles
in 2 wk (P < 0.01; Fig. 2A) and in the number of CL present in their
ovaries (P < 0.01; Fig. 2 B and C).
NeurARKO females did not develop ovulatory dysfunction
displaying multiple corpora lutea when treated with DHT (Fig. 2 B
and C) but displayed apparent acyclicity according to vaginal
smears (Fig. 2A). As androgens can directly impact vaginal epi-
thelium (27), this apparent discrepancy of NeurARKO female
cyclicity may be due to the persistence of direct DHT effects on
the NeurARKO vaginal epithelium. Analysis of serum steroid
levels by liquid chromatography-tandem mass spectrometry (LC-
MS/MS) revealed that DHT was significantly increased in all
groups of DHT-treated mice compared with strain-matched WT
controls (P < 0.01; Table 1). DHT treatment also had significant
effects on serum testosterone (P < 0.01) and 3α- and 3β-diol (P <
0.01) but not dehydroepiandrosterone (DHEA) or progesterone
(P4) concentrations (Table 1). DHT treatment did not influence
serum LH or follicle-stimulating hormone (FSH) levels (Table 1).
Therefore, to conclusively test the hypothesis that extraovarian
AR signaling played a direct role in the development of the PCOS
traits of irregular cycles and ovulatory dysfunction, we performed an
independent experiment that investigated the effect of extra- and
intraovarian AR signaling on these PCOS traits separately. We
undertook reciprocal ovary transplants between WT and ARKO
females and then induced PCOS by long-term DHT treatment. All
intact WT females treated with a blank implant cycled (8 of 8),
whereas 100% of intact WT females treated with DHT were acyclic
(0 of 8; P < 0.01; Fig. 2D). Similarly, compared with intact control
WT females with DHT treatment, 100% of WT hosts with either
WT (0 of 5; P < 0.01) or ARKO (0 of 6; P < 0.01) transplanted
ovaries failed to cycle, and their ovaries displayed no CL (Fig. 2 D
and E). This indicates that a functional AR in the ovary is not
needed for the development of aberrant cycling in PCOS. However,
71% of ARKO hosts with WT transplanted ovaries (i.e., with pre-
served AR signaling) cycled and their ovaries exhibited CL. This
indicates that extraovarian AR actions are required for the devel-
opment of the PCOS traits of aberrant estrous cycles and ovulatory
dysfunction (Fig. 2 D and E). Histologically, ovaries collected from
all DHT-treated WT (WT, NeurWT, or GCWT) and GCARKO
females displayed the classic polycystic appearance, whereas ARKO
and NeurARKO ovaries did not display that phenotype (Figs. 2C
and 3 C and D). Ovarian weight is increased in human PCOS but
decreased in this rodent PCOS model (3, 28). DHT treatment in-
duced a significant decrease in ovary weight in all genotypes (P <
0.01) except for DHT-treated ARKO females, which remained
comparable to control ARKO ovaries (Fig. 3A).
Atretic cyst-like follicles were not present in any of the control
WT ovaries (WT, NeurWT, or GCWT; Figs. 2C and 3 B and C),
but after DHT-induced PCOS all females in these groups dis-
played a significant increase in the prevalence of cystic follicles
(P < 0.05; Figs. 2C and 3 B–D). Although non-DHT (blank
implant)–treated ARKO females exhibited a few cystic follicles,
DHT treatment to induce PCOS did not increase the numbers,
consistent with global AR inactivation preventing DHT-induced
cyst development. Neuron-specific loss of AR signaling signifi-
cantly reduced (P < 0.05) but did not fully protect against the
development of DHT-induced cystic follicles in NeurARKO
ovaries, but was much less than that observed in DHT-treated
WT and GCARKO ovaries (Figs. 2C and 3 B and C).
Neuron but Not Granulosa Cell AR Signaling Is Required for the
Reduction in Large Antral Follicle Health in the PCOS Mouse Model.
In agreement with previous studies using this PCOS mouse
model (21), antral follicle populations were not altered by DHT-
induced PCOS in any treated groups (Fig. S2). However, DHT
treatment induced the PCOS trait of a significant increase in the
proportion of morphologically unhealthy follicles in WT,
NeurWT, and GCWT females, at both the small (P < 0.01) and
large (P < 0.05) antral developmental stages (Fig. 4 A and B),
whereas global AR insensitivity prevented the development of
unhealthy antral follicles by DHT treatment of ARKO females
(Fig. 4 A and B). NeurARKO ovaries displayed a protection
from DHT-induced increases in unhealthy large (Fig. 4B) but not
small (P < 0.01; Fig. 4A) antral follicles. However, a granulosa
cell-specific loss of AR signaling did not protect against the
DHT-induced increase in unhealthy small (P < 0.05) or large
(P < 0.05) antral follicles in GCARKO ovaries (Fig. 4 A and B).
Large antral follicles in DHT-treated WT, NeurWT, and GCWT
ovaries displayed a reduction in granulosa cell-layer thickness (P <
0.01; Fig. 4 C and E, i and ii) but a significant increase in theca cell-
layer area (P < 0.01; Fig. 4 D and E, iii and iv). These features were
fully prevented by a global loss of AR signaling (Fig. 4 C and D).
Granulosa cell-specific loss of AR signaling inhibited the develop-
ment of diminished granulosa cell layers but not the increase in
theca cell area (P < 0.05; Fig. 4 C and D). Neuron-specific loss of
AR signaling did not protect against DHT-induced diminished
granulosa cell layers (P < 0.05) or an increase in theca cell-layer
area (P < 0.01) in NeurARKO antral follicles (Fig. 4 C and D).
Fig. 1. Experimental design. For this study, PCOS was induced in wild-type,
global, neuron-specific, and granulosa cell-specific androgen receptor knockout
mice by s.c. inserting dihydrotestosterone implants in the mice for 3 mo. Control
mice were implanted with blank implants. Body weight, estrous cycling, blood
pressure, fasting glucose, oral glucose tolerance, and insulin tolerance were
assessed before collection of serum and tissues at 16 wk of age.





















Neuron but Not Granulosa Cell AR Signaling Is Required for the
Development of Obesity in the PCOS Mouse Model. All wild-type
groups (WT, NeurWT, or GCWT) that received DHT treatment
exhibited a significant increase in body weight (P < 0.01; Fig. 5A) and
parametrial (P < 0.01; Fig. 5B), retroperitoneal (P < 0.01), inguinal
(P < 0.05), and mesenteric fat-pad weights (P < 0.05). However, both
global (ARKO) and neuron (NeurARKO) AR inactivation fully
prevented this DHT-induced increase in body and fat-pad weights
(Fig. 5). In contrast, a granulosa cell-specific loss of AR signaling did
not inhibit the development of obesity, with GCARKO females dis-
playing a significant DHT-induced increase in body weight (P < 0.01)
and parametrial (P < 0.01), retroperitoneal (P < 0.01), inguinal (P <
0.05), and mesenteric (P < 0.05) fat-pad weights (Fig. 5 A and B).
A Loss of Neuron but Not Granulosa Cell AR Signaling Partially
Protects Against the Development of Adipocyte Hypertrophy in the
PCOS Mouse Model. DHT treatment induced a significant de-
crease in serum adiponectin levels in all DHT-treated groups
(P < 0.01; Fig. 6A), except in global ARKO females, where DHT
did not change serum adiponectin levels (Fig. 6A).
All WT groups exhibited a marked DHT-induced increase in
adipocyte cell size (P < 0.01; Fig. 6 B and C), but this was fully
prevented by global loss of AR signaling (Fig. 6 B and C). DHT
treatment also resulted in adipocyte hypertrophy in NeurARKO
(P < 0.01) and GCARKO (P < 0.01) mice compared with
genotype-matched control mice (Fig. 6 B and C). However, the
degree of adipocyte hypertrophy observed in DHT-treated
Fig. 2. Neuron but not granulosa cell AR signaling is required for the development of anovulation in the PCOS mouse model. Loss of extraovarian AR
signaling ameliorates the development of acyclicity and anovulation in the PCOS mouse model. (A) Average number of full estrous cycles completed in a 2-wk
period, confirming DHT-induced acyclicity in WT mice and showing no development of acyclicity in DHT-induced PCOS ARKO female mice. Data are the
mean ± SEM; n = 5 to 9 per genotype/treatment group. (B) Average number of corpora lutea per ovary, showing no development of anovulation in DHT-
induced PCOS ARKO or NeurARKO female mice. Data are the mean ± SEM; n = 3 to 5 per genotype/treatment group. (C) Histological sections of repre-
sentative ovaries from each treatment group, showing the maintenance of ovulations (indicated by the presence of corpora lutea) in DHT-induced PCOS
ARKO and NeurARKO ovaries. (D) Percentage of cycling females in a 2-wk period, showing no development of acyclicity in DHT-induced PCOS ARKO
ovariectomized females transplanted with WT ovaries. (E) Histological sections of representative ovaries from each treatment group, showing corpora lutea
in DHT-induced PCOS ARKO ovariectomized females transplanted with WT ovaries, indicative of recent ovulation. G, genotype; ns, no significant difference;
T, DHT treatment; *, significant difference; star, corpora lutea; triangle, arrested antral follicle. (Magnification: 10×.) (*P < 0.05, two-way ANOVA.)
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NeurARKO females was significantly less than that exhibited in
all DHT-treated WT (P < 0.01) and GCARKO (P < 0.01) par-
ametrial fat pads (Fig. 6 B and C).
Fasting glucose levels were significantly increased in all WT
mice (WT, NeurWT, or GCWT) after DHT treatment (P < 0.05;
Fig. 6D). Global loss of AR signaling eliminated this effect but
DHT-treated NeurARKO (P < 0.01) and GCARKO (P < 0.01)
mice still exhibited significantly raised fasting glucose levels (Fig.
6D). Similarly, an effect of DHT treatment was apparent with
regard to overall glucose tolerance (two-way ANOVA main ef-
fect, P < 0.01; Fig. 6E), although DHT treatment had no effect
on insulin tolerance (Fig. S3).
Neuron but Not Granulosa Cell AR Signaling Is Required for the
Development of Dyslipidemia in the PCOS Mouse Model. Increased
cholesterol levels were present in all DHT-treated wild-type
groups (P < 0.01; Fig. 7A) but not in DHT-treated global and
neuron-specific ARKO females. DHT-treated GCARKO mice
still displayed the DHT-induced increase in serum cholesterol
levels (Fig. 7A). DHT treatment had a significant effect on serum
triglyceride levels (two-way ANOVA main effect, P < 0.01; Fig.
7B) with an increase in triglycerides in all three wild-type groups
(WT, NeurWT, or GCWT), whereas this effect was prevented in
ARKO and NeurARKO but not GCARKO female mice (Fig.
7B). These results suggest that DHT-induced dyslipidemia re-
quires a functional AR in neurons but not in granulosa cells.
Systolic blood pressure was affected by DHT treatment alone
(two-way ANOVA main effect, P < 0.05), but this effect was
independent of changes in AR genotype (Fig. 7C).
Wild-type mice (WT, NeurWT, or GCWT) treated with DHT
displayed a 10- to 20-fold increase in hepatic lipid staining
compared with controls (P < 0.01; Fig. 7 D and E). Global loss of
the AR protected against the development of DHT-induced
hepatic steatosis in ARKO females. GCARKO DHT-treated
mice experienced a significant increase in lipid accumulation in
the liver (P < 0.01). Loss of neuron AR partially protected
against DHT-induced hepatic steatosis, as lipid accumulation in
DHT-treated NeurARKO females was significantly less than
that exhibited in all DHT-treated WT (P < 0.01) and GCARKO
(P < 0.01) livers (Fig. 7 D and E).
Discussion
Although hyperandrogenism is a key trait of PCOS (5) and experi-
mentally induces a range of reproductive, endocrine, and metabolic
PCOS characteristics in various animal models (8–10), the tissue- or
organ-specific mechanisms through which androgens elicit these key
aspects of the PCOS phenotype remain unclear. In the current study,
we provide evidence that supports AR signaling as an important
mediator in the development of features of experimental PCOS
(Table 2). Our data demonstrate that, in particular, extraovarian
neuroendocrine AR sites of androgen action are predominantly
involved in the pathogenesis of multiple key PCOS characteristics.
This provides strong experimental support for recent GWAS find-
ings that highlight the importance of gonadotropin action in the
genetic origins of susceptibility to PCOS (24–26). In concert, these
Table 1. Characterization of hormone profiles
Genotype/treatment group
DHT, ng/mL T, ng/mL DHEA, ng/mL 3α-diol + 3β-diol, ng/mL P4, ng/mL LH, ng/mL FSH, ng/mL
Gns,T*,GxT* G*,T*,GxTns G*,Tns,GxTns G*,T*,GxTns Gns,Tns,GxTns Gns,Tns,GxTns Gns,Tns,GxTns
WT control 0.11 ± 0.05 0.11 ± 0.01 0.13 ± 0.02 0.24 ± 0.02 1.49 ± 0.61 0.94 ± 0.12 3.29 ± 0.38
WT DHT 0.52 ± 0.18* 0.01 ± 0.01 0.08 ± 0.02 0.09 ± 0.02 0.98 ± 0.17 0.90 ± 0.05 4.01 ± 0.58
ARKO control 0.08 ± 0.02 0.19 ± 0.08 0.11 ± 0.01 0.30 ± 0.09 0.95 ± 0.14 0.95 ± 0.23 4.80 ± 0.76
ARKO DHT 0.19 ± 0.03* 0.12 ± 0.03 0.08 ± 0.02 0.20 ± 0.04 1.18 ± 0.14 1.09 ± 0.11 3.97 ± 0.33
NeurWT control 0.06 ± 0.01 0.06 ± 0.02 0.06 ± 0.01 0.12 ± 0.02 0.99 ± 0.17 0.53 ± 0.22 3.80 ± 0.50
NeurWT DHT 0.42 ± 0.08* 0.01 ± 0.00 0.06 ± 0.01 0.07 ± 0.01 1.07 ± 0.19 0.64 ± 0.21 3.48 ± 0.47
NeurARKO control 0.05 ± 0.00 0.05 ± 0.02 0.08 ± 0.01 0.13 ± 0.03 0.84 ± 0.21 0.56 ± 0.22 2.68 ± 0.43
NeurARKO DHT 0.78 ± 0.15* 0.01 ± 0.00 0.07 ± 0.01 0.08 ± 0.01 1.45 ± 0.37 0.92 ± 0.08 3.72 ± 0.73
GCWT control 0.09 ± 0.02 0.03 ± 0.01 0.11 ± 0.03 0.14 ± 0.03 1.28 ± 0.58 0.87 ± 0.16 3.16 ± 0.51
GCWT DHT 0.57 ± 0.11* 0.01 ± 0.00 0.12 ± 0.03 0.13 ± 0.03 0.59 ± 0.16 0.75 ± 0.14 6.64 ± 1.84
GCARKO control 0.09 ± 0.02 0.07 ± 0.02 0.15 ± 0.03 0.21 ± 0.02 1.64 ± 0.79 0.95 ± 0.21 4.66 ± 0.85
GCARKO DHT 0.41 ± 0.07* 0.01 ± 0.00 0.19 ± 0.05 0.20 ± 0.05 1.94 ± 0.52 0.89 ± 0.13 3.56 ± 0.61
Serum concentrations of dihydrotestosterone, testosterone, dehydroepiandrosterone, 5α-androstane-3α,17β-diol, 5α-androstane-3β,17β-diol, progester-
one, luteinizing hormone, and follicle-stimulating hormone. Data are the mean ± SEM; n = 4 to 9 per genotype/treatment group.
*Significant difference compared with strain-matched WT control female mice.
Fig. 3. Global and neuron but not granulosa cell loss of AR signaling pro-
tects against the development of the classic polycystic ovarian phenotype in
the PCOS mouse model. (A) Ovary weights, confirming DHT-induced re-
duction in ovarian weight in WT mice, and showing no reduction in ovarian
weight in DHT-induced PCOS ARKO female mice. Data are the mean ± SEM;
n = 5 to 9 per genotype/treatment group. (B) Average number of atretic cyst-
like follicles per ovary, displaying no significant development of cysts in DHT-
induced PCOS ARKO females. Data are the mean ± SEM; n = 4 ovaries per
genotype/treatment group. (C) Histological sections of representative ova-
ries, showing development of the classic PCOS ovarian phenotype in DHT-
induced PCOS WT but not ARKO and NeurARKO ovaries. (D) Histological
section of a representative cyst found in all groups treated with DHT. Cysts
display a thinned and discordant granulosa cell layer, a dispersed theca cell
layer (arrow), and an oocyte with a fragmented nucleolus that has lost
connection with most or all of its surrounding granulosa cells. G, genotype;
ns, no significant difference; T, DHT treatment; *, significant difference.
(Magnification: 10×.) (*P < 0.05, two-way ANOVA.)





















findings suggest neuroendocrine AR signaling as a key target for the
development of novel mechanism-based PCOS treatments.
Our data show, by combining a DHT-induced PCOS mouse
model with global and tissue- and cell-specific ARKO mouse
models, that the induction of the PCOS traits of acyclicity and
anovulation requires AR signaling. These findings are in agree-
ment with clinical evidence supporting a direct role for androgen
actions in the development of dysfunctional menstrual cycling
and ovulation in PCOS, as prolonged treatment with the AR
antagonist flutamide is reported to restore menstrual-cycle reg-
ularity and ovulation in some women with PCOS (15, 29). In-
terestingly, by contrast, the treatment of women with PCOS with
estrogen blockage, either by antiestrogen (clomiphene citrate) or
an aromatase inhibitor (letrozole) that increases FSH secretion,
is rapidly effective at inducing ovulation (30). This implies that
the hypothalamic–pituitary feedback response in PCOS women
is functional but that the longer time to effective treatment by
androgen blockade may involve more complex, possibly multistep
underlying mechanisms of androgen-mediated effects, compared
with the more direct mode of action of estrogen blockade. Impor-
tantly, our findings highlight the importance of extraovarian AR
actions in the pathogenesis of ovulatory dysfunction in PCOS. We
show that females treated with DHT display aberrant ovulatory
function when they have fully functional AR actions (intact WT
females and ovariectomized WT females bearing WT ovary trans-
plants) or a loss of AR signaling in the ovary only (GCARKO fe-
males and ovariectomized WT females bearing ARKO ovary
transplants). However, females with an extraovarian loss of AR ac-
tions (NeurARKO females and ovariectomized ARKO females
bearing WT ovary transplants) are protected against DHT-induced
reduction in ovulation, indicated by reduced numbers of corpora
lutea. This suggests that hyperandrogenism-induced PCOS requires
AR actions in neurons and that the AR in granulosa cells is less in-
volved in the development of PCOS acyclicity. There was a discrep-
ancy between the ovulatory function and cyclicity in NeurARKO and
a lack of an overall significant effect on serum P4 and LH, most likely
due to all cycling mice being collected on the afternoon of diestrus,
when serum P4 and LH levels are very low. Nevertheless, the pres-
ence of corpora lutea in NeurARKO ovaries conclusively confirms
the occurrence of recent ovulations. In addition, by undertaking
Fig. 4. Global and neuron but not granulosa cell loss of AR signaling protects against the reduction in large antral follicle health in the PCOS mouse model.
(A) Percentage of unhealthy small antral follicles per ovary, confirming DHT-induced increase in unhealthy small antral follicles in WT mice and showing no
significant decrease in small antral follicle health in DHT-induced PCOS ARKO ovaries. Data are the mean ± SEM; n = 4 ovaries per genotype/treatment group.
(B) Percentage of unhealthy large antral follicles per ovary, showing no significant decrease in large antral follicle health in DHT-induced PCOS ARKO or
NeurARKO female mice. Data are the mean ± SEM; n = 4 ovaries per genotype/treatment group. (C) Average thickness of granulosa cell layer per follicle,
displaying no reduction in granulosa cell-layer thickness in DHT-induced PCOS ARKO or GCARKO ovaries. Data are the mean ± SEM; n = 7 to 24 follicles per
genotype/treatment group. (D) Average percentage of theca area per follicle, showing no significant increase in theca cell area in DHT-induced PCOS ARKO
ovaries. Data are the mean ± SEM; n = 7 to 24 follicles per genotype/treatment group. (E) Histological sections representing the effects of DHT on granulosa
cell-layer thickness (ii, double-ended arrow) and percentage of theca area (iv, white line) compared with controls (i and iii, respectively). G, genotype; ns, no
significant difference; T, DHT treatment; *, significant difference. (Magnification: 10×.) (*P < 0.05, two-way ANOVA.)
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reciprocal ovary transplants between WT and ARKO females, we
decisively proved that extraovarian AR signaling is crucial in the de-
velopment of the PCOS traits of irregular cycles and ovulatory
dysfunction. Taken together with the recent GWAS findings that
implicate alterations in gonadotropin secretion in the origins of
PCOS (24–26), our findings support the previous hypothesis that
hyperandrogenism may impair neuronal circuits in the brain, leading
to a disruption in sex steroid feedback mechanisms and abnormal
gonadotrophin secretion, and subsequent ovulatory dysfunction (31,
32). Current evidence from a mouse PCOS model points to a role
for androgen excess in promoting impaired progesterone-sensitive
gamma-aminobutyric acid (GABA)ergic input to GnRH neurons
within the arcuate nucleus of the hypothalamus (32). Although
species differences occur between humans and rodents in the site of
action of positive estradiol feedback required to trigger the ovulatory
LH surge (33), it is clear that alterations in GnRH pulse generation
are present in women with PCOS (34).
Classic PCOS multicystic ovaries were observed in all DHT-
treated WT groups, whereas this was prevented by global and
neuronal loss of AR actions, confirming that AR-mediated an-
drogen action is required for the development of this key feature
of PCOS. Similarly, the PCOS ovarian morphological features of
reduced follicular health and antral follicle granulosa cell-layer
attenuation but theca cell-layer hypertrophy were induced by
DHT in all WT mice but were not present in DHT-treated
ARKO females. Furthermore, large antral follicle health was
maintained in DHT-treated NeurARKO ovaries, whereas gran-
ulosa cell-wall thickness was not attenuated in GCARKO fe-
males. This finding, together with the observation that a few
DHT-treated GCARKO females display intermittent cycles and
some corpora lutea, implies that in addition to extraovarian
androgen action, additional loci of ovarian AR actions are in-
volved in mediating the PCOS reproductive phenotype.
Obesity is very common among women with PCOS and in turn
leads to more severe hyperandrogenism (5, 35). We observed
significant increases in body and fat-pad weights in all DHT-
treated WT females, whereas global and neuron-specific dis-
ruption of AR signaling protected females from increased adiposity,
implying that hyperandrogenism is directly involved in the high
prevalence of obesity in women with PCOS. Supportive clinical evi-
dence comes from findings that obese PCOS women consuming a
hypocaloric diet together with an androgen antagonist (flutamide)
exhibited additional favorable decreases in visceral fat compared with
diet alone (36, 37).
Adipocyte dysfunction is also linked to PCOS pathogenesis
(38, 39). Adiponectin, postulated to be a beneficial adipokine
due to its insulin-sensitizing property and antiatherogenic action
(40), is reduced in women with PCOS (41). Treatment with
adiponectin in a rat model of PCOS ameliorates the PCOS
phenotype by reversing acyclicity and PCOS ovarian features,
and also improves glucose homeostasis (42). Serum adiponectin
levels were reduced in our PCOS mouse model, and this effect
was protected by global loss of AR function but not by neuron-
or granulosa cell-specific loss of AR actions. Altered adipose
structure has been reported in PCOS women (43) and is linked
with androgen excess, as prenatally androgenized female mon-
keys display impaired adipogenesis (44). Adipocyte hypertrophy
and hepatic steatosis (resembling nonalcoholic fatty liver dis-
ease) were exhibited in all DHT-treated wild-type groups but
absent in global ARKO females. Granulosa cell-specific loss of
AR signaling did not protect against these lipid metabolic PCOS
traits, but a neuron-specific loss of AR actions did offer partial
protection, implying that other sites of AR signaling are required
for full development of these traits. Although hypertrophic adi-
pocytes are inherently insulin-resistant, insulin resistance was not
present in any of the DHT-treated mice. Nevertheless, glucose
homeostasis was consistently impaired, with elevated fasting
glucose levels observed in all DHT-treated wild-type groups as
well as neuron- and granulosa cell-specific ARKO females,
whereas global AR loss prevented the fasting hyperglycemic
effects of DHT treatment. Altered glucose homeostasis in con-
junction with the increase in hepatic steatosis observed in DHT-
treated wild-type groups indicates a significant role for AR sig-
naling in regulating glycogenolysis. Dyslipidemia, a key risk factor
for cardiovascular disease, was observed in all DHT-treated wild-
type females. Global or neuron-specific loss of AR signaling pre-
vented DHT-induced dyslipidemia, as opposed to mice lacking
granulosa cell AR, which developed the condition. Further studies
are needed to understand how central AR signaling in particular
leads to the lipid metabolic disturbance of PCOS. However, the
findings that increased s.c. fat mass and cholesterol levels induced by
a high-fat diet can be alleviated in ovariectomized female mice
treated with DHT (45) indicate that a balance in direct AR actions is
required to maintain normal metabolic function.
By combining unique global and cell-specific ARKO mouse
models with a PCOS mouse model, we have revealed that
hyperandrogenism, acting directly via the AR and independent
of estrogenic effects, is required for the development of several
key PCOS traits in an experimental mouse model. None of the
inducible features of PCOS observed in WT mice were gener-
ated in mice with a global AR inactivation, indicating that AR-
mediated androgen actions are critical in the pathogenesis of
these traits. Our present findings extend our previous findings
that global androgen insensitivity prevents the induction of ex-
perimental PCOS features in mature mice (18). Moreover, we
provide evidence to support a hypothesis that the development
of many key PCOS traits does not require AR signaling in gran-
ulosa cells but rather that anovulation, impaired antral follicle
health, obesity, and lipid metabolic disturbance are all dependent
Fig. 5. Global and neuron but not granulosa cell loss of AR signaling pro-
tects against the development of obesity in the PCOS mouse model. (A) Body
weight, confirming DHT-induced increased body weight in WT mice and
showing no significant increase in body weight in DHT-induced PCOS ARKO
or NeurARKO female mice. Data are the mean ± SEM; n = 5 to 9 mice per
genotype/treatment group. (B) Parametrial fat deposit weight, showing no
significant increase in adiposity in DHT-induced PCOS ARKO or NeurARKO
female mice. Data are the mean ± SEM; n = 5 to 9 per genotype/treatment
group. (C) Representative dual-energy X-ray absorptiometry images, show-
ing no development of obesity in DHT-induced PCOS ARKO female mice. G,
genotype; ns, no significant difference; T, DHT treatment; *, significant
difference. (*P < 0.05, two-way ANOVA.)





















on a functional neuronal AR signaling network. However, neither
NeurARKO nor GCARKO mouse models fully protected against
the development of all PCOS traits. This indicates that the devel-
opment of some PCOS pathology requires direct AR-mediated
androgen actions acting via other sites, or are a downstream re-
sponse to the altered PCOS environment. These findings
demonstrate the complexity of the mechanisms regulating PCOS
pathogenesis, and support the notion that the development of
PCOS involves hyperandrogenic actions acting within multiple
tissues. Taken together, our findings provide strong evidence that
hyperandrogenism plays a direct pathogenic role involving a
neuroendocrine site of action in the development of key PCOS
traits, and support a more tissue- and/or AR-mediated targeted
approach in the development of novel therapeutic treatments.
Materials and Methods
Mice. Mice were maintained under standard housing conditions (ad libitum
access to food and water in a temperature- and humidity-controlled, 12-h
light/dark environment) at the ANZAC Research Institute. All surgical pro-
cedures were carried out under ketamine/xylazine anesthesia, whereas
nonsurgical procedures were carried out under an isoflurane inhalation
anesthetic. All procedures were approved by the Sydney Local Health District
Animal Welfare Committee within National Health and Medical Research
Council guidelines for animal experimentation.
Experimental Design. To elucidate the site of AR-mediated androgen actions
in the etiology of PCOS, three mouse lines with site-specific loss of AR sig-
naling were examined: (i) androgen receptor knockout mice with global loss
of AR signaling; (ii) neuron-specific ARKO mice with brain-specific loss of AR
signaling; and (iii) granulosa cell-specific ARKO mice lacking granulosa cell
AR signaling. Each were compared with their relevant wild-type controls. All
six groups were treated without (controls) or with long-term exposure to
dihydrotestosterone postnatally (Fig. 1), which induces PCOS in wild-type
mice as previously described (21) and based on prior reports of DHT in-
duction of experimental PCOS in rats (28) and mice (20). Briefly, 3-wk-old
female mice were implanted with either a 1-cm Silastic implant (i.d.,
1.47 mm; o.d., 1.95 mm; Dow Corning; 508-006) containing about 10 mg DHT
or an empty, blank control. All DHT-treated experimental groups exhibited a
Fig. 6. Global loss of AR signaling protects against the reduction in adiponectin levels, adipocyte hypertrophy, and altered glucose homeostasis in the PCOS
mouse model. (A) Serum levels of adiponectin, confirming DHT-induced suppression of serum adiponectin levels in WT mice and showing no significant
reduction in adiponectin levels in DHT-induced PCOS ARKO female mice. Data are the mean ± SEM; n = 5 to 7 per genotype/treatment group. (B) Adipocyte
size, showing no development of adipocyte hypertrophy in DHT-induced PCOS ARKO female mice. Data are the mean ± SEM; n = 3 sections per mouse, 3 mice
per genotype/treatment group. (C) Histological sections of representative parametrial fat pads from each treatment group, showing no development of
adipocyte hypertrophy in DHT-induced PCOS ARKO female mice. (D) Average fasting glucose levels showing no significant increase in glucose levels in DHT-
induced PCOS ARKO female mice. Data are the mean ± SEM; n = 5 to 9 per genotype/treatment group. (E) Area under the curve (AUC) analysis of the oral
glucose tolerance test, showing an overall effect of DHT treatment. Data are the mean ± SEM; n = 5 to 9 per genotype/treatment group. G, genotype; ns, no
significant difference; T, DHT treatment; *, significant difference. (Magnification: 40×.) (*P < 0.05, two-way ANOVA.)
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significant increase in serum DHT levels (Table 1; P < 0.01). Mice were col-
lected after ∼13 wk of drug administration (WT: control n = 7, DHT n = 8;
ARKO: control n = 7, DHT n = 7; NeurWT: control n = 5, DHT n = 5; NeurARKO:
control n = 5, DHT n = 5; GCWT: control n = 8, DHT n = 8; GCARKO: control
n = 9, DHT n = 9), when the mice were ∼16 wk of age.
Generation and Genotyping of ARKO, GCARKO, and NeurARKO Mice. Homo-
zygous female ARKO mice were generated by crossing ARflox mice (46), in
which exon 3 is flanked by loxP sites, with Sox2-Cre mice (47) as a universal
deletor, as previously described (48). Female GCARKO mice were generated by
crossing ARflox mice (46) with AMH-Cre mice (49), as previously reported (23). To
generate female NeurARKO mice, ARflox mice (46) were mated with transgenic
CamKIIα-Cre mice (50). Genomic DNA isolated from toe clip or tail biopsy was
used as a template for PCR genotyping to detect rearrangements in the mouse
Ar gene, as described (22). Mice containing the Sox2-Cre gene or the AMH-Cre
gene were detected using primers and PCR conditions as described (23, 48). Mice
containing the CamKIIα-Cre gene were detected using the following PCR pri-
mers: Cre1: 5′-GGTTCTCCGTTTGCACTC-3′; Cre2: 5′-CTGCATGCACGGGACAGCTCT-3′;
and Cre3: 5′-GCTTGCAGGTACAGGAGGTA-3′. Two products are obtained in Cre-
positive mice: 375 bp for transgenic Cre and 290 bp for endogenous Cre. All
knockout models were confirmed using RT-PCR for appropriate, tissue-specific
inactivation of the AR using RNA extracted from ovary, uterus, brain, and pi-
tuitary (Fig. S4), as described (22). Primers specific for mouse β-actin were used as
an internal control. Baseline phenotypic characteristics of the different ARKO
mouse models are provided in Table S1.
Ovarian Transplantation. Reciprocal paired ovarian transplants were per-
formed between wild-type and ARKO females as well as between wild-type
and wild-type females as surgical controls for the procedure, as previously de-
scribed (51). Females served as both donors and recipients whenever possible.
Four-week-old mice were anesthetized, and each ovary was exposed via a flank
incision. The surrounding bursa was incised and the ovary was gently removed at
the hilum. After excision from the donor, the ovaries were held in cold sterile
saline until placed inside the ovarian bursa of the ovariectomized recipient. A
single stitch of 8-0 silk suture was placed through the incision in the bursa. The
reproductive tract was then returned to its normal anatomical position and the
abdominal wall and skin were closed using 6-0 silk sutures. At the same time as
mice underwent ovarian transplantation, females were also implanted with a
DHT implant or blank implant as described above.
Assessment of Estrous Cycle. Estrous-cycle stage was analyzed using vaginal
epithelial cell smears taken daily for 14 consecutive days (21). Smears were
Fig. 7. Global and neuron but not granulosa cell loss of AR signaling ameliorates the development of dyslipidemia in the PCOS mouse model. (A) Serum
cholesterol levels, confirming DHT-induced increased serum cholesterol in WT mice and showing no significant increase in cholesterol levels in DHT-induced
PCOS ARKO or NeurARKO female mice. Data are the mean ± SEM; n = 5 to 7 per genotype/treatment group. (B) Serum triglyceride levels, showing an overall
effect of DHT treatment and a nonsignificant trend to increased triglyceride levels in all DHT-treated groups, apart from DHT-induced PCOS ARKO and
NeurARKO female mice. Data are the mean ± SEM; n = 5 to 7 per genotype/treatment group. (C) Systolic blood pressure, displaying no significant difference
between control and DHT-treated PCOS mice of any genotype. Data are the mean ± SEM; n = 5 to 9 per genotype/treatment group. (D) Analysis of liver
steatosis by oil red O staining, showing no significant increase in the presence of steatosis in DHT-induced PCOS ARKO female mice. Data are the mean ± SEM;
n = 3 sections per mouse, 3 mice per genotype/treatment group. (D) Histological sections of representative liver sections stained with oil red O, showing
reduced lipid staining in DHT-induced PCOS ARKO livers. G, genotype; ns, no significant difference; T, DHT treatment; *, significant difference. (Magnification:
40×.) (*P < 0.05, two-way ANOVA.)





















collected at the same time each day (10 AM) using 15 μL of 0.9% sterile
saline, transferred to glass slides to air dry. Dry smears were stained with
0.5% toluidine blue before being examined under a light microscope.
Estrous-cycle stage was determined based on the presence or absence of
leukocytes, cornified epithelial cells, and nucleated epithelial cells. Proestrus
was characterized by the presence of mostly nucleated and some cornified
epithelial cells; at the estrus stage, primarily cornified epithelial cells were
present; at metestrus, both cornified epithelial cells and leukocytes were
present; and at diestrus, predominantly leukocytes were present.
Ovary Preparation, Morphological Analysis, and Follicle Health. Dissected
ovaries were weighed, fixed in 4% (volvol) paraformaldehyde overnight at
4 °C, and stored in 70% ethanol before histological processing. Ovaries were
processed through graded alcohols and embedded in glycol methacrylate
resin (Technovit 7100; Heraeus Kulzer). Serial sections of 20 μm were stained
with periodic acid-Schiff and counterstained with hematoxylin. For CL
quantification, whole-section scans of every second section were taken un-
der a light microscope using the EVOS FL Auto System (Life Technologies). To
quantify antral follicle populations and assess follicular health, sections were
examined using an Olympus light microscope with Stereo Investigator
software (MBF Bioscience), as previously described (21). Total numbers of
small antral follicles (oocyte surrounded by greater than five layers of
granulosa cells and/or one or two small areas of follicular fluid), large antral
follicles (containing a single large antrum), preovulatory follicles (a large
antral follicle with an oocyte surrounded by cumulus cells at the end of a
stalk of mural granulosa cells), and atretic cyst-like follicles (large fluid-filled
cysts with an attenuated granulosa cell layer, dispersed theca cell layer, and
an oocyte lacking connection to the granulosa cells; Fig. 3D) were classified
and quantified as previously reported (21, 22). To avoid repetitive counting,
each follicle was only counted in the section where the oocyte’s nucleolus
was visible. For all analyses, large antral follicles and preovulatory follicles
were grouped together and called “large antral follicles.” Follicles were
classified as unhealthy if they contained a degenerate oocyte and/or more
than 10% of the granulosa cells were pyknotic in appearance, as previously
described (21, 22). The proportion of unhealthy follicles per ovary was cal-
culated as the percentage of all follicles at that developmental stage. For all
large antral follicles, granulosa cell-layer thickness and theca cell-layer area
were measured using ImageJ version 1.48 software (open-source, developed
by the National Institutes of Health), as previously reported (21).
Hormone Assays. Blood was collected from females by cardiac exsanguination
under ketamine/xylazine anesthesia, and collected serum was stored at −20 °C.
Mouse serum LH and FSH were determined using a species-specific immu-
nofluorometric assay, as previously described (18). The mouse LH detection
limit was 0.04 ng/mL, intraassay coefficient of variation (CV) was 5.2%, and
interassay CV was 8.6%. The mouse FSH detection limit was 0.1 ng/mL,
intraassay CV was 3.1%, and interassay CV was 7.2%. All immunoassays were
performed in a single batch.
Serum levels of testosterone (T), DHEA, DHT, its two principal metabolites
5α-androstane-3α,17β-diol (3α-diol) and 5α-androstane-3β,17β-diol (3β-diol),
and progesterone were measured in extracts of 100 μL mouse serum by LC-
MS/MS, as previously described (18). The limits of quantitation (defined as
the lowest level that can be detected with a CV of <20%) were 25 pg/mL for
T, 100 pg/mL for DHEA, DHT, 3α-diol, and 3β-diol, and 50 pg/mL for P4.
Adipose Tissue Analysis. Parametrial fat pads were weighed, fixed in 4%
paraformaldehyde, embedded in paraffin, and sectioned at 8 μm. Sections
were stained with hematoxylin and eosin before images were taken for
histomorphometry at 40× magnification under a light microscope using the
EVOS FL Auto System (Life Technologies). Five distinct images were taken
from each of three sections of the fat pad, with at least 200 μm separating
these sections.
Hepatic Steatosis Analysis. Livers were weighed whole before the right lateral
lobe was excised from the whole liver and fixed in 10% neutral buffered
formalin overnight at 4 °C and then soaked in 30% sucrose (vol/vol) for 48 h;
1-cm × 1-cm segments were excised from the lobe and embedded in OCT
compound (Tissue-Tek) before 10-μm sections were cryosectioned and air-
dried onto slides. Slides were stained with oil red O in 60% isopropanol to
visualize lipid deposition, as previously described (52), before histo-
morphometric analysis. ImageJ version 1.48 software (NIH) was used to
quantify oil red O-positive staining. Three separate images were analyzed
from three distinct sections taken at least 200 μm apart.
Insulin and Oral Glucose Tolerance Tests. Insulin tolerance tests (ITTs) and oral
glucose tolerance tests (oGTTs) were carried out as previously reported, with
modifications (52). Mice were fasted for 6 h before a baseline blood glucose
reading, followed by an i.p. injection of 0.75 IU/kg body weight (BW) insulin
(Eli Lilly) or an oral bolus of glucose at 2 g/kg BW. Blood glucose was then
measured at 15, 30, 60, 90, and 120 min. Blood was obtained from a tail
prick, and blood glucose was measured on glucose strips and an Accu-Chek
glucometer (Roche). ITTs and oGTTs were carried out at 16 wk of age.
Table 2. Summary of the effect of global, neuron-specific, and granulosa cell-specific loss of androgen receptor
signaling on the development of PCOS traits
+ DHT
Clinical PCOS trait WT mouse Global loss of AR Neuronal loss of AR Granulosa cell loss of AR
Absent/irregular cycling ✓ ✗ ✓ Partial
Oligo/anovulation ✓ ✗ ✗ ✓
Classic multicystic ovarian appearance ✓ ✗ Partial ✓
Change in ovary weight* ✓ ✗ ✓ ✓
↑Unhealthy small antral follicles ✓ ✗ ✓ ✓
↑Unhealthy large antral follicles ✓ ✗ ✗ ✓
↓Granulosa cell-layer thickness ✓ ✗ ✓ ✗
↑Theca cell-layer thickness ✓ ✗ ✓ ✓
↑Body weight ✓ ✗ ✗ ✓
↑Parametrial fat-pad weight ✓ ✗ ✗ ✓
↑Retroperitoneal fat-pad weight ✓ ✗ ✗ ✓
↑Inguinal fat-pad weight ✓ ✗ ✗ ✓
↑Mesenteric fat-pad weight ✓ ✗ ✗ ✓
Adipocyte hypertrophy ✓ ✗ Partial ✓
↓Adiponectin ✓ ✗ ✓ ✓
Dyslipidemia† ✓ ✗ ✗ ✓
Hepatic steatosis ✓ ✗ Partial ✓
Impaired fasting glucose ✓ ✗ ✓ ✓
✓, clinical PCOS trait present; ✗, clinical PCOS trait not present; partial, effect of DHT evident but not to the same extent seen in
WT mice.
*↑ In humans; ↓ in mice.
†↑Cholesterol + clear trend toward ↑triglycerides.
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Blood Pressure. Blood pressure was measured with an automated tail-cuff
system (MC4000; Hatteras Instruments), as previously described (53). Ani-
mals were acclimatized to the system for 3 d before data being collected on
the fourth day. Animals were conscious at the time of measurement. Mea-
surements were taken at 16 wk of age.
Cholesterol and Triglyceride Assays. Serum levels of triglycerides and total
cholesterol were assayed enzymatically with kits obtained from Wako
(Cholesterol E Kit, 439-17501; Triglyceride Kit, 432-40201).
Adiponectin Assay. Serum levels of total full-length mouse adiponectin were
measured using a Quantikine ELISA Kit from R&D Systems (MRP300)
according to the manufacturer’s instructions. The mean minimum detectable
dose of mouse adiponectin was 0.003 ng/mL. This kit specifically measures
natural and recombinant full-length mouse adiponectin; <0.5% cross-
reactivity is observed with available related molecules.
Statistical Analysis. Statistical analysis was performed using Prism 6 software
(GraphPad Software). Data that were not normally distributed were trans-
formed before analysis using log transformation. Statistical differences were
tested by two-way ANOVA followed by Fisher’s least significant difference
multiple-comparison test as a post hoc test. Proportions were analyzed by
Fisher’s exact test. P values <0.05 were considered statistically significant.
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